Abstract
Awoman in her 60s presented to the otolaryngology clinic with a 1-month history of hoarseness. Her medical history was significant for metastatic colon cancer for which she had received primary surgical therapy in 1999. She subsequently developed lungmetastases and was treated by her oncologist with different combinations of capecitabine, irinotecan, fluorouracil, leucovorin, and oxaliplatin. Following progression despite use of these agents, she received fluorouracil plus bevacizumab, an anti–vascular endothelial growth factor (VEGF) monoclonal antibody. One week after her third cycle of anti-VEGF treatment, she reported new-onset, rapidly progressive hoarseness. On examination, she exhibited severe dysphonia and flexible transnasal laryngoscopy revealed bilateral, symmetric, white membranous true vocal fold lesions sparing the anterior commissure (Figure). Vocal fold mobility was unaffected, but videostroboscopy demonstrated near-complete loss of bilateral mucosal waves. The patient was never a smoker, did not drink alcohol, and had no other symptoms indicative of laryngopharyngeal reflux. Empirical treatment with systemic antifungal therapy had no effect. What is your diagnosis? A B
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Similar Papers
More From: JAMA Otolaryngology–Head & Neck Surgery
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.